CFT8919

About C4 Therapeutics

C4 Therapeutics is a clinical-stage biotech company at the forefront of targeted protein degradation (TPD), a transformative therapeutic modality. Its mission is to design small-molecule degraders that offer a potentially superior approach to traditional inhibition by eliminating, not just inhibiting, disease-causing proteins. The company's strategy is built on its proprietary TORPEDO® platform, a hybrid business model combining internal oncology pipeline development with high-value strategic collaborations with pharmaceutical leaders like Roche and Biogen. Despite a challenging market valuation, C4T is progressing its lead assets, Cemsidomide and CFT8919, through clinical trials in hematologic and solid tumors.

Therapeutic Areas